

Registration Deadline

April 17, 2025

Event registration is limited, so please register early. No refunds will be given after April 17, 2025.



To register, scan QR code or visit <https://rsvp.duke.edu/82w0IV>

Joint Accreditation

In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the International Association for Continuing Education and Training (IACET), American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 14.75 MOC Part 2 points (and patient safety MOC credit) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Credit Statement

Physicians: Duke University Health System. Department of Clinical Education and Professional Development designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nursing: Duke University Health System. Department of Clinical Education and Professional Development designates this activity for up to 14.75 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System. Department of Clinical Education and Professional Development designates this activity for up to 14.75 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-25-146-L04-P



Meet the Expert

Keynote Speaker: Carlos DeCastro, III, MD

Distinguished hematologist-oncologist Dr. DeCastro's career has been marked by a fervent commitment to excellence, compassion, and ground breaking research. He will share his innovative approach to deepen the understanding of PNH as a paradigm for rare diseases. Don't miss this opportunity to gain valuable insight into the future of treating challenging blood disorders.

Additional Highlights

Clinical Quandary:

Submit a challenging patient case for our experts to debate. Submit to tracy.torgerson@duke.edu

Debate Topics:

Amyloidosis, Follicular Lymphoma, CLL novel combinations, racial disparities in AML, DLBCL, and a wide range of hematologic malignancy debates.

Contact/Questions


Beth Tanner, Duke Cancer Network
615 Douglas St., Suite 602, Durham, NC 27705
beth.tanner@duke.edu

25th Annual Duke Debates:

Controversies in the Management of Patients with Hematologic Malignancies

**The Westin
Hilton Head Island
Resort & Spa**

Hilton Head, SC
April 25-27, 2025



Presented by: Duke Cancer Network in
collaboration with Duke Cancer Institute



25th Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies

April 25-27, 2025

Thursday, April 24

Reception in the Grand Ocean Terrace

Friday, April 25

7:00 a.m. Registration and Breakfast - Product Theater #1

SESSION 1: Myeloma

Moderator: *Cristiana Chase, DO*

8:00 a.m. Welcome: *Harry Erba, MD, PhD*

8:05 a.m. What is the Best Approach in Myeloma: CarT vs. Bi Specifics, *Taewoong Choi, MD vs. Jacob Laubach, MD, MPP (Dana-Farber)*

8:45 a.m. In 2025, What is the Role of CarT vs. Transplant in Myeloma, *Yubin Kang, MD vs. Luciano Costa, MD, PhD (Univ. of Alabama)*

9:30 a.m. Break and Product Theater #1 – Heyward Elliott Room

10:15 a.m. Young Myeloma Patients. Is there an Optimal Post-Transplant Management Strategy? *Peter Voorhees, MD (Atrium Health) vs. Ajay Nooka, MD, MPH, FACP (Emory)*

11:00 a.m. What is the Best Approach to Managing the Frail Myeloma Patient in the Community, *Cristiana Chase, DO vs. Sascha Tuchman, MD, MHS (UNC)*

11:45 a.m. Lunch – Grand Ocean Terrace

12:45 p.m. Smoldering Myeloma: Treatment vs. Non-Treatment *Cristiana Chase, DO vs. Peter Voorhees, MD (Atrium Health)*

1:30 p.m. Clinical Quandaries

2:15 p.m. Closing Remarks

2:15 p.m. Pharma Time and Break

SESSION 2: APP Specialty Session

Moderator: *Therese Hennig, PA-C, MPAS*

2:30 p.m. Prehab Oncology and Why it's so Important
Lisa Massa, CLT, PT, WCS

3:00 p.m. AI in Healthcare: Transforming the Practice of Medicine
Anand Chowdhury, MD, MMCI

3:30 p.m. Toxicity Management of Bi-Specifics
Daniel Schrum, PharmD, BCOP

4:00 p.m. Treatment and Management of Myeloproliferative Neoplasms, *Lindsay Rein, MD*

4:30 p.m. How I Approach MDS, *Carlos DeCastro, MD*

5:30 p.m. Reception on the Ocean Front Terrace

Saturday, April 26

7:00 a.m. Registration and Breakfast – Ballroom Foyer and Danner Ballroom

SESSION 3: CLL and Lymphoma

Moderator: *Danielle Brander, MD*

7:55 a.m. Welcome

8:00 a.m. Keynote Address: PNH is the Paradigm for Rare Diseases
Carlos DeCastro, MD

8:45 a.m. CLL Debate: All for One or One for All in 2025? BTKi and BCL2 Combinations in Frontline CLL Treatment.
Pro: Combinations Should be Used – *Deborah Stephens, DO (UNC) vs. Con: BTKi or BCL2i but Not Both – Andrea Sitlinger, MD*

9:30 a.m. Break and Product Theater #2 Heyward/Drayton/Elliott Room

10:15 a.m. Case Based Discussion of Toxicity and Treatment Management in CLL/SLL and FL, *Deborah Stephens, DO (UNC); Andrea Sitlinger, MD and Danielle Brander, MD*

11:00 a.m. State of the Art in 2025: Treatment of Follicular Lymphoma in Frontline and Relapsed/Refractory Setting, *Jonathan Friedberg, MD, MMSc (Rochester)*

11:45 a.m. Lunch – Grand Ocean Terrace

12:45 p.m. Bi-specifics Should be Incorporated Into Frontline Management of DLBCL vs. Reserved for Later Lines.
Pro: All DLBCL Should Receive Frontline – *Alexandra Stefanovic, MD vs. Con: Reserve for Later Lines - Jonathon Cohen, MD, MS (Emory)*

1:30 p.m. All Patients with T cell Lymphoma Should Have NGS/ Molecular Testing Prior to Frontline Therapy vs. Use Reserved in Select or Refractory Patients.
Pro: All T cell Lymphoma Patients have NGS – *Jie Wang, MD, MS vs. Con: NGS only in Select Patients – Matthew Lunning, DO, FACP (Univ. of Nebraska)*

2:15 p.m. Clinical Quandaries in Lymphoma, *Drs. Brander, Cohen, Stefanovic, Wang and Lunning*

2:45 p.m. Closing Remarks

5:30 p.m. VIP Reception in the Koi Pond Garden to Include Platinum and Gold Sponsors and Non-Pharma Attendees

Sunday, April 27

7:00 a.m. Registration and Breakfast – Ballroom Foyer and Danner Ballroom

SESSION 4: Leukemia

Moderator: *Harry Erba, MD, PhD*

7:55 a.m. Welcome

8:00 a.m. Case Presentation and Debate: Ven/HMA is Standard of Care for All Older Patients Regardless of Fitness
Harry Erba, MD, PhD vs. Gail Roboz, MD (Cornell)

8:50 a.m. Case Presentation / Redux/ Panel Discussion
Drs. Erba, Rein and Roboz

9:10 a.m. Essential Thrombocythemia: Diagnosis, Prognosis and Therapeutic Options, *Lindsay Rein, MD*

9:40 a.m. Sickle Cell Gene Therapy vs. Allogeneic HCT,
Adetola Kassim, MD, MS vs. John J. Strouse, MD, PhD

10:20 a.m. Racial Disparity and AML, *Ann-Kathrin Eisfeld, MD (Ohio)*

11:00 a.m. Closing Remarks